SCHEMBL2846716

SCHEMBL2846716

COc1ccc(C=CC(=O)Nc2ccc(Br)cc2C(=O)O)cc1OC

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 7/20 0.73
KMT2A Q03164 7/20 0.73
HPGD P15428 6/20 0.73
SMN1; SMN2 Q16637 6/20 0.73
ALDH1A1 P00352 5/20 0.73
KDM4E B2RXH2 4/20 0.73
TP53 P04637 3/20 0.73
NPC1 O15118 3/20 0.73
RAB9A P51151 3/20 0.73
CYP3A4 P08684 2/20 0.73
HIF1A Q16665 2/20 0.73
NPSR1 Q6W5P4 2/20 0.73
PKM P14618 2/20 0.73
CYP1A2 P05177 2/20 0.73
HSD17B10 Q99714 2/20 0.73
MAPK1 P28482 2/20 0.73
CYP2C9 P11712 1/20 0.73
CYP2C19 P33261 1/20 0.73
ABCC4 O15439 1/20 0.73
HPGDS O60760 1/20 0.73

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2846712 1.00 MEN1 (0.73) MEN1KMT2AHPGDSMN1; SMN2ALDH1A1
SCHEMBL19695969 0.91 MEN1 (0.73) MEN1KMT2AHPGDSMN1; SMN2ALDH1A1
SCHEMBL8640599 0.88 MEN1 (0.77) MEN1KMT2AHPGDSMN1; SMN2ALDH1A1
SCHEMBL4669878 0.88 MEN1 (0.77) MEN1KMT2AHPGDSMN1; SMN2ALDH1A1
SCHEMBL16215149 0.88 HPGD (0.60) MEN1KMT2AHPGDSMN1; SMN2ALDH1A1
SCHEMBL11236190 0.87 MEN1 (0.75) MEN1KMT2AHPGDSMN1; SMN2ALDH1A1
SCHEMBL11236193 0.87 MEN1 (0.75) MEN1KMT2AHPGDSMN1; SMN2ALDH1A1
SCHEMBL2839285 0.87 MAPT (0.79) MEN1KMT2AHPGDSMN1; SMN2ALDH1A1
SCHEMBL2839289 0.87 MAPT (0.79) MEN1KMT2AHPGDSMN1; SMN2ALDH1A1
SCHEMBL11236200 0.86 MEN1 (0.73) MEN1KMT2AHPGDSMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2799427-B1 Therapeutic compounds FIBROTECH THERAPEUTICS PTY LTD (AU) 2018-07-04 EP disclosed
US-9561201-B2 Therapeutic compounds FIBROTECH THERAPEUTICS PTY LTD (AU) 2017-02-07 US disclosed
US-20140357628-A1 THERAPEUTIC COMPOUNDS FIBROTECH THERAPEUTICS PTY LTD (AU) 2014-12-04 US disclosed
EP-2799427-A1 Therapeutic compounds Fibrotech Therapeutics PTY LTD (AU) 2014-11-05 EP disclosed
US-8765812-B2 Therapeutic compounds FIBROTECH THERAPEUTICS PTY LTD (AU) 2014-07-01 US disclosed
EP-2035369-B1 THERAPEUTIC COMPOUNDS FIBROTECH THERAPEUTICS PTY LTD (AU) 2014-06-25 EP disclosed
CN-101600683-B Therapeutic compounds FIBROTECH THERAPEUTICS PTY LTD AU 2013-06-12 CN disclosed
US-20100130497-A1 Therapeutic Compounds FIBROTECH THERAPEUTICS PTY LTD (AU) 2010-05-27 US disclosed
EP-2035369-A1 THERAPEUTIC COMPOUNDS Fibrotech Therapeutics PTY LTD (AU) 2009-03-18 EP disclosed
WO-2008003141-A1 THERAPEUTIC COMPOUNDS FIBROTECH THERAPEUTICS PTY LTD (AU) 2008-01-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140357628-A1 THERAPEUTIC COMPOUNDS NFATC1, AADAC, NAT1 MEN1 2604/4885KMT2A 1715/4885HPGD 630/4885
US-20100130497-A1 Therapeutic Compounds NFATC1, NAT1, AADAC MEN1 2640/4885KMT2A 1798/4885HPGD 536/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.